This treatment reduced H19 levels in the two ETP‐ALL cell lines, HSB‐2 and DU.528, by ~ 60%, while it had no effect on H19 levels in the more mature and kinase inhibitor‐resistant CUTLL1 cells (Fig. 4E). This evidence concerns the gene H19 and acute lymphoblastic leukemia.